Global Antibody Contract Manufacturing Market (2020 to 2030)

News provided by

Mar 30, 2020, 09:45 ET

DUBLIN, March 30, 2020 The "Antibody Contract Manufacturing Market, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.

The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.
A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.
An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.
An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).
Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.
A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.

The report features detailed transcripts of interviews held with the following individuals:

Dietmar Katinger, Chief Executive Officer, Polymun Scientific
David C Cunningham, Director Corporate Development, Goodwin Biotechnology
Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVE ANALYSIS

6. COMPANY PROFILES

7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

8. BENCHMARK ANALYSIS

9. PARTNERSHIPS

10. RECENT EXPANSIONS

11. CAPACITY ANALYSIS

12. DEMAND ANALYSIS

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

14. SWOT ANALYSIS

15. FUTURE OF THE ANTIBODY CMO MARKET

16. INTERVIEW TRANSCRIPTS

17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

AbbVie Contract Manufacturing
Abcuro
Abdi Ibrahim
A-Bio Pharma
ABL
ABL Bio
Absolute Antibody
Abzena
AC Immune
Acticor Biotech
Actinium Pharmaceuticals
Adagene
Affinita Biotech
Affinity Life Sciences
AGC Biologics
Ajinomoto Althea
Alcami
Aldevron
Alethia Biotherapeutics
Allele Biotechnology & Pharmaceuticals
Alligator Bioscience
Alvotech
Annular Biotech
Antibodies Incorporated
Antibody Production Services (division of Life Science Group)
Arabio
Arcus Biosciences
argenx
ASKA Biotech
ASLAN Pharmaceuticals
AURA Biotechnologies
AutekBio
Avid Bioservices
Avioq
Axcellerate Pharma
Batavia Biosciences
Baxter BioPharma Solutions
Bayer
Baylor Scott & White Research Institute
BeiGene
Bharat Serums and Vaccine
BIBITEC
BINEX
BioInvent International
BioLineRx
Biomay
Biomedical Advanced Research and Development Authority (BARDA)
BiosanaPharma
Biosynergy EUROPE
BioTechnique
Biovian
BioVolutions
BioXcellence (Boehringer Ingelheim)
BJ Bioscience
Brii Biosciences
Bristol-Myers Squibb
Bruker
Calypso Biotech
CANbridge
Capralogics
Catalent
Catalent Biologics
Cell Culture Company
Cell Essentials
Celonic
Center of iPS Cell Research and Application, Kyoto University
Cerbios-Pharma
Changchun High & New Technology Industry
ChemPartner
Chiome Bioscience
CinnaGen
Citryll
CMAB Biopharma
CMC Biologics
Cobra Biologics
Compugen
Cook Pharmica
Creative Biolabs
CytoDyn
Cytovance Biologics
DaTaMabs
Diatec Monoclonals
DM Bio
Dyax
And Many Many More!

For more information about this report visit https://www.researchandmarkets.com/r/ta244f

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets